US law firm Motley Rice appeals $396 mln opioid fee award
By Brendan Pierson
June 24 (Reuters) - U.S.law firm Motley Rice is appealing its award of $396 million for its work on litigation against the drug industry over the opioid crisis that resulted in $46 billion in nationwide settlements.
The firm said it would appeal the award, which represents 18.6% of a $2.13 billion pool of fees to be divided among dozens of law firms, in a notice filed Friday in Cleveland federal court. It did not say how much it was asking for or on what basis it was challenging the award.
Motley Rice had already won a bump in fees after objecting earlier in the allocation process, up from 17.2%, or $366 million, according to a June 7 court filing.
The firm did not immediately respond to a request for comment.
Several other firms have secured awards in the hundreds of millions of dollars and have not appealed them.
Other firms that filed notices of appeal are Spangenberg Shibley & Liber; Kelley Ferraro; Crueger Dickinson; Stranch, Jennings & Garvey; and Weisman, Kennedy & Berris. All of those firms received less than 2% of the funds.
The fees stem from settlements that local and Native American tribal governments have reached with drugmakers Johnson & Johnson JNJ.N, AbbVie ABBV.N and Teva Pharmaceutical Industries TEVA.TA; distributors Cencora COR.N, McKesson MCK.N and Cardinal Health CAH.N; and pharmacies CVS CVS.N, Walgreens Boots Alliance WBA.O and Walmart WMT.N.
They do not include a settlement of up to $6 billion with bankrupt OxyContin maker Purdue Pharma, which is funded by that company's Sackler family owners in exchange for a shield from future lawsuits. The U.S. Supreme Court is currently weighing whether that settlement is legal.
Opioid settlements, including both the nationwide deals and separate agreements negotiated by individual states, now total well over $50 billion. However, many state and local governments have yet to develop detailed plans for how they will spend the money to remedy the harms caused by opioids.
More than 800,000 people in the United States died of opioid overdoses from 1999 through 2023, according to data from the U.S. Centers for Disease Control and Prevention. Plaintiffs in the lawsuits say that drugmakers downplayed the drugs' risks, and that distributors and pharmacies ignored red flags that they were being diverted into illegal channels, fueling an epidemic of addiction.
Read more:
Top law firms in US opioid lawsuits to get hundreds of millions in fees
US Supreme Court torn over Purdue Pharma bankruptcy settlement
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
